PLAC™ test for identification of individuals at increased risk for coronary heart disease

References

• American Heart Association. Heart and Stroke Statistics – 2004 Update. American Heart Association, TX, USA, 5–6 (2003).
   Google Scholar
• Ross R. Atherosclerosis – an inflammatory disease. N. Engl. J. Med.340, 115–126 (1999).
   PubMed Web of Science ®Google Scholar
• Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest.88, 1785–1792 (1991).
   PubMed Web of Science ®Google Scholar
• Holvoet P, Mertens A, Verhamme P et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol.21, 844–848 (2001).
   PubMed Web of Science ®Google Scholar
• Sanchez-Quesada JL, Camacho M, Anton R et al. Electronegative LDL of FH subjects: chemical characterization and induction of chemokine release from human endothelial cells. Atherosclerosis166, 261–270 (2003).
   PubMedGoogle Scholar
• Hodis HN, Kramsch DM, Avogaro P et al. Biochemical and cytotoxic characteristics of an in vivo circulating oxidized low-density lipoprotein (electronegative LDL). J. Lipid Res.35, 669–677 (1994).
   PubMed Web of Science ®Google Scholar
• De Castellarnau C, Sanchez-Quesada JL, Benitez S et al. Electronegative LDL from normolipemic subjects induces IL-8 and monocyte chemotactic protein secretion by human endothelial cells. Arterioscler. Thromb. Vasc. Biol.20, 2281–2287 (2000).
   PubMed Web of Science ®Google Scholar
• Demuth K, Myara I, Chappey B et al. A cytotoxic electronegative LDL subfraction is present in human plasma. Arterioscler. Thromb. Vasc. Biol.16, 773–783 (1996).
   PubMed Web of Science ®Google Scholar
• Palmantier R, Dulioust A, Maiza H, Benveniste J, Ninio E. Biosynthesis of paf-acether. XIV. Paf-acether output in murine peritoneal macrophages is regulated by the level of acetylhydrolase. Biochem. Biophys. Res. Commun.162, 475–482 (1989).
   PubMed Web of Science ®Google Scholar
• Elstad MR, Stafforini DM, McIntyre TM, Prescott SM, Zimmerman GA. Platelet-activating factor acetylhydrolase increases during macrophage differentiation: a novel mechanism that regulates accumulation of platelet-activating factor. J. Biol. Chem.264, 8467–8470 (1989).
   PubMed Web of Science ®Google Scholar
• Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase: purification and properties. J. Biol. Chem.262, 4223–4230 (1987).
   PubMed Web of Science ®Google Scholar
• Stafforini DM, McIntyre TM, Carter ME, Prescott SM. Human plasma platelet-activating factor acetylhydrolase: association with lipoprotein particles and role in the degradation of platelet-activating factor. J. Biol. Chem.262, 4215–4222 (1987).
   PubMed Web of Science ®Google Scholar
• Tselepis AD, Dentan C, Karabina SA, Chapman MJ, Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler. Thromb. Vasc. Biol.15, 1764–1773 (1995).
   PubMed Web of Science ®Google Scholar
• Benitez S, Sanchez-Quesada JL, Ribas V et al. Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction. Circulation108, 92–96 (2003).
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Karabina SA, Tambaki AP et al. Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J. Lipid Res.43, 256–263 (2002).
   PubMed Web of Science ®Google Scholar
• Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor acetylhydrolases. J. Biol. Chem.272, 17895–17898 (1997).
   PubMedGoogle Scholar
• Stafforini DM, Satoh K, Atkinson DL et al. Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J. Clin. Invest.97, 2784–2791 (1996).
   PubMed Web of Science ®Google Scholar
• Tjoelker LW, Eberhardt C, Unger J et al. Plasma platelet-activating factor acetylhydrolase is a secreted phospholipase A2 with a catalytic triad. J. Biol. Chem.270, 25481–25487 (1995).
   PubMed Web of Science ®Google Scholar
• Tew DG, Southan C, Rice SQ et al. Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins. Arterioscler. Thromb. Vasc. Biol.16, 591–599 (1996).
   PubMedGoogle Scholar
• Stremler KE, Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase: oxidatively fragmented phospholipids as substrates. J. Biol. Chem.266, 11095–11103 (1991).
   PubMed Web of Science ®Google Scholar
• Turunen P, Jalkanen J, Heikura T et al. Adenovirus-mediated gene transfer of Lp-PLA2 reduces LDL degradation and foam cell formation in vitro.J. Lipid Res.45, 1633–1639 (2004).
   PubMedGoogle Scholar
• Hase M, Tanaka M, Yokota M, Yamada Y. Reduction in the extent of atherosclerosis in apolipoprotein E-deficient mice induced by electroporation-mediated transfer of the human plasma platelet-activating factor acetylhydrolase gene into skeletal muscle. Prostaglandins Other Lipid Mediat.70, 107–118 (2002).
   PubMed Web of Science ®Google Scholar
• Theilmeier G, De Geest B, Van Veldhoven PP et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice. FASEB J.14, 2032–2039 (2000).
   PubMed Web of Science ®Google Scholar
• Quarck R, De Geest B, Stengel D et al. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation103, 2495–2500 (2001).
   PubMed Web of Science ®Google Scholar
• Hakkinen T, Luoma JS, Hiltunen MO et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerosis lesions. Arterioscler. Thromb. Vasc. Biol.19, 2909–2917 (1999).
   PubMed Web of Science ®Google Scholar
• Singh U, Zhong S, Xiong M, Li TB, Sniderman A, Teng BB. Increased plasma non-esterified fatty acids and platelet-activating factor acetylhydrolase are associated with susceptibility to atherosclerosis in mice. Clin. Sci. (Lond.)106, 421–432 (2004).
   PubMed Web of Science ®Google Scholar
• Opal S, Laterre PF, Abraham E et al. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a Phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit. Care Med.32, 332–341 (2004).
   PubMed Web of Science ®Google Scholar
• Miwa M, Miyake T, Yamanaka T et al. Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J. Clin. Invest.82, 1983–1991 (1988).
   PubMed Web of Science ®Google Scholar
• Balta G, Gurgey A, Kudayarov DK, Tunc B, Altay C. Evidence for the existence of the PAF acetylhydrolase mutation (Val279Phe) in non-Japanese populations: a preliminary study in Turkey, Azerbaijan, and Kyrgyzstan. Thromb. Res.101, 231–234 (2001).
   PubMedGoogle Scholar
• Hiramoto M, Yoshida H, Imaizumi T, Yoshimizu N, Satoh K. A mutation in plasma platelet-activating factor acetylhydrolase (Val279→Phe) is a genetic risk factor for stroke. Stroke28, 2417–2420 (1997).
   PubMed Web of Science ®Google Scholar
• Yamada Y, Yoshida H, Ichihara S, Imaizumi T, Satoh K, Yokota M. Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis150, 209–216 (2000).
   PubMedGoogle Scholar
• Shimokata K, Yamada Y, Kondo T et al. Association of gene polymorphisms with coronary artery disease in individuals with or without nonfamilial hypercholesterolemia. Atherosclerosis172, 167–173 (2004).
   PubMed Web of Science ®Google Scholar
• Unno N, Nakamura T, Kaneko H et al. Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in japan. J. Vasc. Surg.32, 263–267 (2000).
   PubMed Web of Science ®Google Scholar
• Unno N, Nakamura T, Mitsuoka H et al. Association of a G994→T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with risk of abdominal aortic aneurysm in Japanese. Ann. Surg.235, 297–302 (2002).
   PubMed Web of Science ®Google Scholar
• Ishihara M, Iwasaki T, Nagano M et al. Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients. J. Hum. Genet.49, 302–307 (2004).
   PubMed Web of Science ®Google Scholar
• Bell R, Collier DA, Rice SQ et al. Systematic screening of the LDL-PLA2 gene for polymorphic variants and case-control analysis in schizophrenia. Biochem. Biophys. Res. Commun.241, 630–635 (1997).
   PubMed Web of Science ®Google Scholar
• Kruse S, Mao XQ, Heinzmann A et al. The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am. J. Hum. Genet.66, 1522–1530 (2000).
   PubMed Web of Science ®Google Scholar
• Abuzeid AM, Hawe E, Humphries SE, Talmud PJ. Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis168, 283–238 (2003).
   PubMed Web of Science ®Google Scholar
• Ninio E, Tregouet D, Carrier J-L et al. Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Hum. Mol. Genet.13, 1341–1351 (2004).
   PubMed Web of Science ®Google Scholar
• Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis150, 413–419 (2000).
   PubMed Web of Science ®Google Scholar
• Packard CJ, O’Reilly DS, Caslake MJ et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med.343, 1148–1155 (2000).
   PubMed Web of Science ®Google Scholar
• Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women. J. Am. Coll. Cardiol.38, 1302–1306 (2001).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Hoogeveen RC, Bang H et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation109, 837–842 (2004).
   PubMed Web of Science ®Google Scholar
• Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation110, 1903–1908 (2004).
   PubMed Web of Science ®Google Scholar
• Hofman A. Lipoprotein-associated phospholipase A2 is associated with risk of coronary heart disease and stroke. The Rotterdam study. Presented at European Society of Cardiology Congress 2004, Munich, Germany August 31, 2004.
   Google Scholar
• Shahar E, Chambless LE, Rosamond WD et al. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke34, 623–631 (2003).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Presented at 5th Annual Conference on Arteriosclerosis, Thrombosis, and Vascular Biology. San Francisco, CA, May 8 (2004).
   Google Scholar
• New test predicts heart risk. FDA Consum.37, 6 (2003).
   Google Scholar
• Dada N, Kim NW, Wolfert RL. Lp-PLA2: an emerging biomarker of coronary heart disease. Expert Rev. Mol. Diagn.2, 17–22 (2002).
   PubMedGoogle Scholar
• Tselepis AD, Karabina SA, Stengel D, Piedagnel R, Chapman MJ, Ninio E. N-linked glycosylation of macrophage-derived PAF-AH is a major determinant of enzyme association with plasma HDL. J. Lipid Res.42, 1645–1654 (2001).
   PubMedGoogle Scholar
• Tselepis AD, Chapman MJ. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler. Suppl.3, 57–68 (2002).
   PubMed Web of Science ®Google Scholar
• Marathe GK, Zimmerman GA, McIntyre TM. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J. Biol. Chem.278, 3937–3947 (2003).
   PubMed Web of Science ®Google Scholar